Ardelyx Net Cash Flow 2013-2025 | ARDX

Ardelyx net cash flow from 2013 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Ardelyx Net Cash Flow 2013-2025 | ARDX

Ardelyx net cash flow from 2013 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.5B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.9B
Daiichi Sankyo, - (DSNKY)$42.7B
BeOne Medicines - (ONC)$27.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$18.9B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.4B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.3B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.1B
Hypermarcas (HYPMY)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B